GIUV2023-582
Currently, the group's main research activity is focused on the study of high-grade serous ovarian cancer (HGSOC) and triple-negative breast cancer (TNBC).We essentially focused on the study of the generation of drug resistance through cell models, murine models and patient samples.
- Study of AXL-GAS6 as a mechanism of resistance to PARP inhibitors in COSAG and CMTN through replicative stress and immunomodulation
- Analysis of the role of the p53-Aurora kinase pathway as potential predictive biomarkers and therapeutic targets in COSAG and CMTN
- Analysis of AXL and the epithelial-mesenchymal transition as a mechanism of resistance to PARP inhibitors in high-grade ovarian cancer
- Study of the role of trabectedin in reversal to resistance to platinum and PARP inhibitors
- Study of the generation of drug resistance in high-grade serous ovarian cancer and triple negative breast.The group focuses on studying the generation of mechanisms of resistance to different drugs used in clinical practice for ovarian cancer, specifically high-grade serous ovarian cancer (HGSOC) and triple negative breast cancer (TNBC).
| Name | Nature of participation | Entity | Description |
|---|---|---|---|
| BEGOÑA PINEDA MERLO | Director | Universitat de València | |
| Research team | |||
| M ELENA OBRADOR PLA | Collaborator | Universitat de València | |
| JOSE ALEJANDRO PEREZ FIDALGO | Collaborator | Universitat de València | |
| JOSE ALEJANDRO PEREZ FIDALGO | Collaborator | Hospital Clínico Universitario de Valencia | Doctor |
| JUAN JOSÉ MARTINEZ PRETEL | Collaborator | Universitat de València - Estudi General | UVEG PhD student |
- -
- Physiology
- Cancer
- cáncer; mama; ovario; resistencias; fármacos
- PHARMACEUTICALS
